SFI Health™ EMEA Announces the Launch in Portugal of Equazen® Food Supplements, the Brand Developed to Support Cognitive Needs
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is excited to announce that Equazen® products will soon be available in Portugal. The company specializes in clinically researched products in microbiome, cognition, and well-being.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250226258206/en/
Discover Equazen®, a science-based food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages. (Graphic: Business Wire)
This marks a significant step forward in SFI Health™ EMEA's ongoing European expansion, following the exclusive license-in agreement signed in February 2024 with Eqyon Healthcare Solutions, a local distributor specialized in healthcare products. Under the terms of the agreement, Eqyon will use its sales and marketing expertise to distribute Equazen® range in pharmacies and parapharmacies.
Equazen® is a trusted global brand offering science-based nutritional solutions to support brain health and cognitive function. Equazen® products feature a unique combination of essential fatty acids (Omega 3 and Omega 6), proven in over 15 clinical studies to support learning, concentration, and healthy brain development.
Matthew Brabazon, GM of SFI Health™ EMEA commented: “We are excited to offer our science-backed Equazen® solutions to Portuguese consumers, who are becoming more proactive in supporting their cognitive needs. Our entry in Portugal is another step of our development plan to grow in the region by widening our partners network and customer base.”
Mr. Nuno Carvalho, CEO of Eqyon, added: “We believe Equazen® products will make a meaningful impact in our market, thanks to their high-quality ingredients and well-documented benefits. We are proud to bring Equazen® back to Portugal and will work closely with SFI Health™ EMEA to strengthen confidence in natural solutions among healthcare professionals and consumers."
Brain health supplements are one of the fastest growing segments in the global food supplements market: in Europe, between 2023 and 2030, the market is expected to grow at a compound annual rate of 12.5%, driven by increased awareness of cognitive and mental health.
SFI Health™ EMEA and Equazen® are present in several markets, including Spain, United Kingdom, Switzerland, Poland, Czech, Slovak, the Netherlands, the Nordics and the Baltics. The company aims at further widening Equazen® distribution to unlock the potential sales of the brand and make the most of the growing brain health supplements market.
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information go to sfihealth.com or follow us SFI Health on LinkedIn.
About Eqyon Healthcare Solutions
Eqyon Healthcare Solutions is a customer-focused company dedicated to optimizing healthcare supply chains. By leveraging strategic partnerships and innovative solutions, we help healthcare providers, pharmacies, and institutions improve efficiency, reduce costs, and enhance patient care.
We are committed to addressing the challenges within the healthcare sector through effective, evidence-based solutions. As part of this commitment, we are excited to reintroduce Equazen® to the Portuguese market. Equazen® aligns with our mission to offer natural, scientifically-backed products that promote cognitive health and well-being. In partnership with trusted global brands like Equazen®, we expand access to high-quality, proven solutions that improve lives.
At Eqyon Healthcare Solutions, we aim to be a leading provider of efficient healthcare solutions, continuously transforming challenges into opportunities and ensuring excellence in customer care.
For more information, visit eqyon.eu and follow Eqyon Healthcare Solutions on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226258206/en/
Contacts
For more information
SFI Health™ EMEA
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com
Eqyon
Nuno Carvalho & CEO
e-mail address: nuno.carvalho@eqyon.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 04:00:00 EEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 23:03:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2025: Sales were $1.01 billion, flat in US dollars and up 2 percent in constant currency, compared
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 22:32:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
One out of Three Secure Civil IDs Delivered Each Year Is Powered by Thales29.4.2025 17:50:00 EEST | Press release
Each year, Thales powers one in three smart civil IDs (official electronic documents) issued worldwide, highlighting the company’s key role in shaping the future of identities and helping governments and citizens transition smoothly to digital. With its Civil Identity Suite, Thalesenables the issuance and management of both physical and digital identities, as well as all means of enrolling citizens and enabling seamless ID verification for access to services, both in-person and online. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429687137/en/ Thales Civil Id Suite (Photo: Thales Shutterstock) Thales, a global leader in advanced technologies and #1 global leader in ID documents, has recently earned the new title of #1 provider of Digital ID solutions as recognized by Juniper Research (2024). With unmatched experience and scale, Thales empowers governments to modernise their identity systems, ensuring they meet the deman
Andersen Global Enhances European Valuation Capabilities through Collaboration with Value & Risk Valuation Services29.4.2025 16:30:00 EEST | Press release
Andersen Global continues to strengthen its valuation capabilities through a Collaboration Agreement with Value & Risk Valuation Services, a prominent European valuation firm headquartered in Germany with offices in Luxembourg and Austria. Founded in 1996, Value & Risk Valuation Services is a management-owned firm specializing in the valuation of financial assets across diverse asset classes and varying complexities. The firm also provides complementary services, including independent price verification (IPV), risk analysis, and transaction cost analysis. Since 2009, the company has been led by Gil Bender, who is dedicated to delivering high-quality, client-centric valuation solutions. As one of the few European providers offering external valuation services in compliance with the European Alternative Investment Fund Managers Directive (AIFMD), Value & Risk upholds the highest industry standards for regulatory compliance and service excellence. “Since our inception, we have focused on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom